Concepts (134)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pancreas Transplantation | 1 | 2024 | 38 | 0.920 |
Why?
|
| Antigens, Surface | 2 | 2014 | 117 | 0.850 |
Why?
|
| Hepatectomy | 1 | 2024 | 110 | 0.850 |
Why?
|
| Kidney Failure, Chronic | 2 | 2024 | 880 | 0.830 |
Why?
|
| Graft Rejection | 3 | 2024 | 590 | 0.790 |
Why?
|
| Dendritic Cells | 2 | 2014 | 414 | 0.710 |
Why?
|
| CD4-Positive T-Lymphocytes | 2 | 2014 | 472 | 0.710 |
Why?
|
| Hypersensitivity | 2 | 2023 | 185 | 0.660 |
Why?
|
| Graft Survival | 2 | 2024 | 536 | 0.610 |
Why?
|
| Allergens | 3 | 2023 | 252 | 0.570 |
Why?
|
| Liver Cirrhosis | 1 | 2024 | 832 | 0.560 |
Why?
|
| Antigens, CD1 | 2 | 2014 | 20 | 0.560 |
Why?
|
| Paramyxoviridae Infections | 2 | 2014 | 47 | 0.550 |
Why?
|
| Anti-Asthmatic Agents | 2 | 2020 | 112 | 0.550 |
Why?
|
| Asthma | 3 | 2024 | 755 | 0.500 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2024 | 920 | 0.500 |
Why?
|
| Glycoproteins | 2 | 2014 | 370 | 0.470 |
Why?
|
| Liver Neoplasms | 1 | 2024 | 1292 | 0.440 |
Why?
|
| Postoperative Complications | 4 | 2024 | 3071 | 0.440 |
Why?
|
| Respiratory Syncytial Virus Infections | 2 | 2014 | 344 | 0.420 |
Why?
|
| HIV Infections | 1 | 2024 | 1895 | 0.410 |
Why?
|
| Cytokines | 3 | 2014 | 1286 | 0.370 |
Why?
|
| Lung Transplantation | 6 | 2011 | 321 | 0.360 |
Why?
|
| Survival Rate | 4 | 2024 | 2056 | 0.350 |
Why?
|
| Disease Management | 1 | 2014 | 525 | 0.330 |
Why?
|
| Kidney Transplantation | 1 | 2015 | 642 | 0.330 |
Why?
|
| Follow-Up Studies | 5 | 2024 | 5165 | 0.270 |
Why?
|
| Prognosis | 2 | 2024 | 4627 | 0.240 |
Why?
|
| Laryngopharyngeal Reflux | 1 | 2024 | 7 | 0.230 |
Why?
|
| Vocal Cord Dysfunction | 1 | 2024 | 8 | 0.230 |
Why?
|
| Risk Factors | 5 | 2024 | 10280 | 0.230 |
Why?
|
| Bronchiolitis Obliterans | 5 | 2011 | 40 | 0.220 |
Why?
|
| Thrombomodulin | 2 | 2014 | 24 | 0.220 |
Why?
|
| HIV | 1 | 2024 | 180 | 0.210 |
Why?
|
| Fatty Liver | 1 | 2024 | 187 | 0.200 |
Why?
|
| Dermatitis, Atopic | 1 | 2023 | 41 | 0.200 |
Why?
|
| Drug Hypersensitivity | 1 | 2023 | 95 | 0.190 |
Why?
|
| Retrospective Studies | 6 | 2024 | 16301 | 0.180 |
Why?
|
| Gastroesophageal Reflux | 1 | 2024 | 326 | 0.180 |
Why?
|
| Arachis | 1 | 2021 | 73 | 0.180 |
Why?
|
| Peanut Hypersensitivity | 1 | 2021 | 75 | 0.170 |
Why?
|
| Granulomatous Disease, Chronic | 1 | 2020 | 66 | 0.170 |
Why?
|
| Humans | 20 | 2024 | 125040 | 0.160 |
Why?
|
| Adult | 9 | 2024 | 29625 | 0.160 |
Why?
|
| Ganciclovir | 2 | 2008 | 103 | 0.150 |
Why?
|
| Epitopes, B-Lymphocyte | 1 | 2017 | 31 | 0.140 |
Why?
|
| Middle Aged | 6 | 2024 | 26925 | 0.140 |
Why?
|
| Epitopes, T-Lymphocyte | 1 | 2017 | 125 | 0.130 |
Why?
|
| Male | 10 | 2024 | 61438 | 0.130 |
Why?
|
| Vaccines, Synthetic | 1 | 2017 | 317 | 0.130 |
Why?
|
| Female | 10 | 2024 | 66722 | 0.130 |
Why?
|
| Cytomegalovirus Infections | 2 | 2008 | 219 | 0.130 |
Why?
|
| Epitopes | 1 | 2017 | 434 | 0.120 |
Why?
|
| Respiratory Tract Infections | 2 | 2009 | 272 | 0.120 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2015 | 1052 | 0.120 |
Why?
|
| Macrophages, Alveolar | 1 | 2014 | 49 | 0.110 |
Why?
|
| Tissue and Organ Procurement | 2 | 2015 | 224 | 0.110 |
Why?
|
| Metapneumovirus | 1 | 2014 | 51 | 0.110 |
Why?
|
| Treatment Failure | 1 | 2015 | 338 | 0.110 |
Why?
|
| National Heart, Lung, and Blood Institute (U.S.) | 1 | 2014 | 42 | 0.110 |
Why?
|
| Respiratory Syncytial Viruses | 1 | 2014 | 147 | 0.110 |
Why?
|
| Europe | 1 | 2014 | 353 | 0.100 |
Why?
|
| Antiviral Agents | 2 | 2008 | 752 | 0.100 |
Why?
|
| Databases, Factual | 2 | 2015 | 1179 | 0.100 |
Why?
|
| Interferon-alpha | 1 | 2014 | 230 | 0.100 |
Why?
|
| Reoperation | 1 | 2015 | 833 | 0.100 |
Why?
|
| Vaccination | 1 | 2017 | 961 | 0.100 |
Why?
|
| Child | 6 | 2023 | 24334 | 0.100 |
Why?
|
| Flow Cytometry | 1 | 2014 | 797 | 0.090 |
Why?
|
| Multivariate Analysis | 1 | 2015 | 1437 | 0.090 |
Why?
|
| Proportional Hazards Models | 1 | 2015 | 1356 | 0.090 |
Why?
|
| Time Factors | 4 | 2015 | 6327 | 0.090 |
Why?
|
| Lymphocyte Activation | 1 | 2013 | 697 | 0.090 |
Why?
|
| Cells, Cultured | 2 | 2014 | 3054 | 0.090 |
Why?
|
| Precision Medicine | 1 | 2014 | 319 | 0.090 |
Why?
|
| Clarithromycin | 1 | 2011 | 126 | 0.090 |
Why?
|
| Consensus | 1 | 2014 | 639 | 0.090 |
Why?
|
| Evidence-Based Medicine | 1 | 2014 | 634 | 0.080 |
Why?
|
| Hepatitis B Antibodies | 1 | 2009 | 24 | 0.080 |
Why?
|
| Heart-Lung Transplantation | 1 | 2009 | 23 | 0.080 |
Why?
|
| Aged | 4 | 2024 | 19862 | 0.080 |
Why?
|
| United States | 2 | 2015 | 10904 | 0.080 |
Why?
|
| Age Factors | 1 | 2015 | 2817 | 0.080 |
Why?
|
| Lung Diseases, Fungal | 1 | 2008 | 32 | 0.070 |
Why?
|
| Opportunistic Infections | 1 | 2008 | 77 | 0.070 |
Why?
|
| Bronchoscopy | 1 | 2008 | 152 | 0.070 |
Why?
|
| Practice Guidelines as Topic | 1 | 2014 | 1266 | 0.070 |
Why?
|
| Lung | 1 | 2014 | 1499 | 0.070 |
Why?
|
| Cell Differentiation | 1 | 2014 | 1899 | 0.070 |
Why?
|
| Tissue Donors | 1 | 2009 | 494 | 0.060 |
Why?
|
| Adolescent | 5 | 2021 | 19316 | 0.060 |
Why?
|
| Cell Proliferation | 1 | 2013 | 2309 | 0.060 |
Why?
|
| Anti-Bacterial Agents | 2 | 2023 | 2427 | 0.060 |
Why?
|
| Risk Assessment | 1 | 2015 | 3452 | 0.060 |
Why?
|
| Severity of Illness Index | 1 | 2014 | 2905 | 0.060 |
Why?
|
| Young Adult | 3 | 2015 | 9042 | 0.060 |
Why?
|
| Child, Preschool | 2 | 2021 | 13975 | 0.060 |
Why?
|
| Pneumonia | 3 | 2014 | 323 | 0.050 |
Why?
|
| Erythema | 1 | 2023 | 24 | 0.050 |
Why?
|
| Penicillins | 1 | 2023 | 154 | 0.050 |
Why?
|
| Infant, Newborn | 1 | 2015 | 8193 | 0.050 |
Why?
|
| Omalizumab | 1 | 2020 | 33 | 0.040 |
Why?
|
| Desensitization, Immunologic | 1 | 2021 | 103 | 0.040 |
Why?
|
| Infant | 1 | 2015 | 12456 | 0.040 |
Why?
|
| Immunoglobulin E | 1 | 2020 | 160 | 0.040 |
Why?
|
| Administration, Oral | 1 | 2021 | 684 | 0.040 |
Why?
|
| Comorbidity | 1 | 2024 | 1532 | 0.040 |
Why?
|
| Animals | 2 | 2017 | 34246 | 0.040 |
Why?
|
| Transplantation, Homologous | 2 | 2011 | 666 | 0.040 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2020 | 318 | 0.040 |
Why?
|
| Combined Modality Therapy | 1 | 2020 | 1239 | 0.030 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2020 | 512 | 0.030 |
Why?
|
| Antibodies, Monoclonal | 1 | 2020 | 1034 | 0.030 |
Why?
|
| Inflammation Mediators | 1 | 2014 | 243 | 0.030 |
Why?
|
| Airway Obstruction | 1 | 2014 | 165 | 0.030 |
Why?
|
| Mice, Inbred BALB C | 1 | 2014 | 1002 | 0.020 |
Why?
|
| Virus Replication | 1 | 2014 | 608 | 0.020 |
Why?
|
| Cohort Studies | 2 | 2009 | 4810 | 0.020 |
Why?
|
| Bronchoalveolar Lavage | 1 | 2008 | 23 | 0.020 |
Why?
|
| Gram-Positive Bacterial Infections | 1 | 2009 | 76 | 0.020 |
Why?
|
| Gram-Negative Bacterial Infections | 1 | 2009 | 87 | 0.020 |
Why?
|
| Syndrome | 1 | 2011 | 1121 | 0.020 |
Why?
|
| Hepatitis B | 1 | 2009 | 160 | 0.020 |
Why?
|
| Multicenter Studies as Topic | 1 | 2008 | 275 | 0.020 |
Why?
|
| Mycoses | 1 | 2009 | 118 | 0.020 |
Why?
|
| Postoperative Period | 1 | 2008 | 334 | 0.020 |
Why?
|
| Monitoring, Physiologic | 1 | 2008 | 377 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2008 | 1504 | 0.010 |
Why?
|
| Lung Diseases | 1 | 2008 | 384 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2008 | 1698 | 0.010 |
Why?
|
| Disease Models, Animal | 1 | 2014 | 4397 | 0.010 |
Why?
|
| Length of Stay | 1 | 2008 | 1307 | 0.010 |
Why?
|
| Treatment Outcome | 2 | 2008 | 12384 | 0.010 |
Why?
|
| Incidence | 1 | 2009 | 3136 | 0.010 |
Why?
|